Jidinum

Sitagliptin, the active ingredient in Jidinum, is a dipeptidyl peptidase-4 (DPP‑4) inhibitor presented as a tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control.

GNH USA supplies Jidinum as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sitagliptin is used in the management of type 2 diabetes mellitus, either alone or in combination with other antidiabetic agents.

- Type 2 diabetes mellitus (monotherapy): improves glycemic control by enhancing insulin secretion and reducing glucagon release. - Type 2 diabetes mellitus (combined with metformin): provides additional glucose lowering when metformin alone is insufficient. - Type 2 diabetes mellitus (combined with insulin): helps achieve target HbA1c while allowing lower insulin doses.

Sitagliptin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient mild to moderate pain. - Upper respiratory infection: cough, sore throat, or congestion. - Nausea: occasional mild gastrointestinal discomfort. - Diarrhea: loose stools that resolve spontaneously. - Arthralgia: joint pain without swelling.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain requiring immediate medical attention. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Bullous pemphigoid: blistering skin disorder. - Hepatic injury: elevated liver enzymes or hepatitis. - Joint inflammation: severe or persistent joint swelling. - Hypoglycemia: especially when combined with insulin or sulfonylureas.

When prescribing or dispensing sitagliptin, consider the following safety measures.

- Renal impairment: assess kidney function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - History of pancreatitis: avoid use due to risk of recurrence. - Elderly patients: monitor for hypoglycemia when used with insulin secretagogues. - Concomitant medications: review for potential drug interactions. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Sitagliptin can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase sitagliptin exposure. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of sitagliptin. - ACE inhibitors: monitor renal function and electrolytes. - Warfarin: observe INR for potential changes. - Rifampin: may reduce sitagliptin plasma levels. - Digoxin: monitor for altered digoxin concentrations.